Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-507 in Polycythemia Vera
NCT07012109Phase 1Recruiting
- Sponsor
- BeBetter Med
- Start
- Jun 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of BEBT-507 in polycythemia vera (PV) (2 arms), sponsored by BeBetter Med. Primary endpoints: Maximum Tolerated Dose up to 52 weeks, Dose-Limiting Toxicity up to 52 weeks and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
BEBT-507
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT07012109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012109.